In gliomas harboring the H3K27M mutation, dopamine receptor D2 is overexpressed and dopamine receptor D5 is suppressed, resulting in enhancement of sensitivity to a dopamine receptor D2 antagonist [103]. This evidence concerns the gene DRD2 and glioma.